Ireland's Glanbia FY25 revenue rises on segment volume growth

Glanbia

25/02/2026 07:18

Overview

The Irish Better Nutrition firm reported preliminary FY25 revenue up 2.3% yr/yr

Adjusted EPS for FY25 declined 3.4% yr/yr

Company announced €100 mln share buyback authorization for 2026

Outlook

Glanbia expects adjusted EPS growth of 7% to 11% constant currency in 2026

Company anticipates operating cash conversion of 85%+ in FY 2026

Glanbia plans capital expenditure of $100 mln to $110 mln in 2026

Result Drivers

VOLUME GROWTH - Co reported volume growth across all segments, driving overall revenue increase

WHEY COSTS IMPACT - Record whey input costs negatively affected Performance Nutrition EBITDA margin

SEGMENTAL GROWTH - Health & Nutrition and Dairy Nutrition segments saw strong demand, boosting revenue

Company press release: ID:nRSY2494Ua

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Revenue
$3.95 bln
FY Adjusted EPS
$1.35
FY Net Income
$283.90 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the food processing peer group is "buy"

Wall Street's median 12-month price target for Glanbia PLC is €18.00, about 9% above its February 24 closing price of €16.52

The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 12 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)